Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 8:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 607 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bone Development Clear all
Enrolling by invitation Phase 2Phase 3 Interventional

A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of Weekly Subcutaneous Doses With TransCon CNP in Children and Adolescents With Achondroplasia

NCT05929807
View directory record Official record
Conditions
Achondroplasia
Interventions
TransCon CNP
Drug
Lead sponsor
Ascendis Pharma Growth Disorders A/S
Industry
Eligibility
3 Years to 15 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2039
U.S. locations
8
States / cities
Little Rock, Arkansas • Aurora, Colorado • Wilmington, Delaware + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 30, 2026, 8:40 PM EDT
Completed Phase 1 Interventional

Imatinib Mesylate, Daunorubicin, and Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia

NCT00268229
View directory record Official record
Conditions
Leukemia
Interventions
cytarabine, daunorubicin hydrochloride, imatinib mesylate
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 15, 2013 · Synced Oct 30, 2026, 8:40 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Magnetic Mini-Mover Procedure to Treat Pectus Excavatum

NCT00466206
View directory record Official record
Conditions
Pectus Excavatum
Interventions
Magnetic Mini-Mover Procedure (3MP), Magnatract (external magnet in a removable external brace), 3MP (Magnetic Mini-Mover Procedure)
Device · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
8 Years to 14 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 1, 2016 · Synced Oct 30, 2026, 8:40 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Validation of Macimorelin as a Test for Adult Growth Hormone Deficiency

NCT02558829
View directory record Official record
Conditions
Growth Hormone Deficiency With Pituitary Anomalies
Interventions
Macimorelin, Insulin
Drug
Lead sponsor
AEterna Zentaris
Industry
Eligibility
18 Years to 65 Years
Enrollment
157 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
5
States / cities
Torrance, California • Austin, Texas • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2018 · Synced Oct 30, 2026, 8:40 PM EDT
Terminated Not applicable Interventional

A Prospective Study of NuCel® in Cervical Spine Fusion

NCT02381067
View directory record Official record
Conditions
Spondylosis, Spinal Stenosis, Spondylolisthesis, Intervertebral Disc Disease, Intervertebral Disc Degeneration
Interventions
NuCel with Allograft Bone
Other
Lead sponsor
NuTech Medical, Inc
Industry
Eligibility
21 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Marietta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 30, 2026, 8:40 PM EDT
Completed Phase 2 Interventional Results available

Long Term Follow up Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children

NCT02500316
View directory record Official record
Conditions
Growth Hormone Deficiency (GHD)
Interventions
MOD-4023
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
3 Years to 11 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Oct 30, 2026, 8:40 PM EDT
Completed No phase listed Observational

Examination of Clinical and Laboratory Abnormalities in Patients With Defective DNA Repair: Xeroderma Pigmentosum, Cockayne Syndrome, or Trichothiodystrophy

NCT00001813
View directory record Official record
Conditions
Cockayne Syndrome, Skin Neoplasms, Xeroderma Pigmentosum, Trichothiodystrophy Syndromes, Genodermatosis
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
6 Weeks to 100 Years
Enrollment
709 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 30, 2026, 8:40 PM EDT
Terminated Phase 1 Interventional Results available

Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML

NCT01849276
View directory record Official record
Conditions
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Blastic Phase Chronic Myelogenous Leukemia, Recurrent Adult Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions
metformin hydrochloride, cytarabine, laboratory biomarker analysis
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 31, 2019 · Synced Oct 30, 2026, 8:40 PM EDT
Not listed Phase 2 Interventional

Vosoritide for Short Stature in Turner Syndrome

NCT05849389
View directory record Official record
Conditions
Turner Syndrome, Short Stature
Interventions
Vosoritide
Drug
Lead sponsor
Roopa Kanakatti Shankar, MBBS, MS
Other
Eligibility
3 Years to 11 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 24, 2024 · Synced Oct 30, 2026, 8:40 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Network Of Clinical Research Studies On Craniosynostosis, Skull Malformations With Premature Fusion Of Skull Bones

NCT03025763
View directory record Official record
Conditions
Craniosynostosis
Interventions
Craniosynostosis Network Environmental Survey, 2D/3D Photography, Buccal Swab Cell Sampling, Blood sampling, Skin Biopsy, Tissues from a Clinically Indicated Procedure, Pre-operative CT Scan Image Files.
Other · Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
Up to 80 Years
Enrollment
2,145 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2028
U.S. locations
15
States / cities
Davis, California • Hartford, Connecticut • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2025 · Synced Oct 30, 2026, 8:40 PM EDT
Recruiting No phase listed Observational

Biopsychosocial Risk Influences on the Development and Generation of Early-Onset Chronic Pain

NCT07602595
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis (JIA), Fibromyalgia, Lupus, Scoliosis, Pectus Excavatum, Chronic Pain, Musculoskeletal Pain
Interventions
Not applicable- observational study
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
14 Years to 26 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 30, 2026, 8:40 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Allogeneic Transplantation For Severe Osteopetrosis

NCT00775931
View directory record Official record
Conditions
Severe Osteopetrosis
Interventions
umbilical cord blood transplantation, Campath-1H, Total Lymphoid Irradiation, Cyclophosphamide, Busulfan, Fludarabine monophosphate, marrow graft transplantation
Procedure · Drug · Radiation
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
1 Day to 45 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 30, 2026, 8:40 PM EDT
Completed Phase 2Phase 3 Interventional

IGF-I/IGFBP-3 Therapy in Children and Adolescents With Growth Hormone Insenitivity Syndrome (GHIS) Such as Laron Syndrome

NCT00368173
View directory record Official record
Conditions
Growth Hormone Insensitivity Syndrome (GHIS), Laron Syndrome
Interventions
rhIGF-I/rhIGFBP-3
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
2 Years to 18 Years
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 13, 2012 · Synced Oct 30, 2026, 8:40 PM EDT
Recruiting No phase listed Observational

Longitudinal Study of Neurodegenerative Disorders

NCT03333200
View directory record Official record
Conditions
MLD, Krabbe Disease, ALD, MPS I, MPS II, MPS III, Vanishing White Matter Disease, GM3 Gangliosidosis, PKAN, Tay-Sachs Disease, NP Deficiency, Osteopetrosis, Alpha-Mannosidosis, Sandhoff Disease, Niemann-Pick Diseases, MPS IV, Gaucher Disease, GAN, GM1 Gangliosidoses, Morquio Disease, S-Adenosylhomocysteine Hydrolase Deficiency, Batten Disease, Pelizaeus-Merzbacher Disease, Leukodystrophy, Lysosomal Storage Diseases, Purine Nucleoside Phosphorylase Deficiency, Multiple Sulfatase Deficiency Disease
Interventions
Palliative Care, Hematopoetic Stem Cell Transplantation
Other · Biological
Lead sponsor
University of Pittsburgh
Other
Eligibility
Not listed
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2035
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 30, 2026, 8:40 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Physical Activity and Community EmPOWERment Project

NCT06740162
View directory record Official record
Conditions
Intellectual Disability, Neurodevelopmental Disorders, Autism Spectrum Disorder, Down Syndrome, Fragile X Syndrome, Cri-du-Chat Syndrome, De Lange Syndrome, Mental Retardation, X-Linked, Prader-Willi Syndrome, Rubinstein-Taybi Syndrome, Trisomy 13 Syndrome, WAGR Syndrome, Williams Syndrome
Interventions
PACE Program
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
376 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
2
States / cities
Fayetteville, Arkansas • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 30, 2026, 8:40 PM EDT
Completed Phase 2 Interventional

S0301 Cyclosporine, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

NCT00066794
View directory record Official record
Conditions
Leukemia
Interventions
filgrastim, sargramostim, cyclosporine, cytarabine, daunorubicin hydrochloride
Biological · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
56 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
97
States / cities
Mobile, Alabama • Tucson, Arizona • Orange, California + 62 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 30, 2026, 8:40 PM EDT
Terminated Phase 3 Interventional Results available

Multicenter,Single-arm Study to Evaluate Efficacy, Safety, & Pharmacokinetics of Denosumab in Children w/ OI

NCT02352753
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
Denosumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
2 Years to 17 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
13
States / cities
Los Angeles, California • Torrance, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2022 · Synced Oct 30, 2026, 8:40 PM EDT
Terminated Phase 2 Interventional Results available

Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT02030405
View directory record Official record
Conditions
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Recurrent Adult Acute Myeloid Leukemia
Interventions
Ixazomib
Drug
Lead sponsor
Steven E. Coutre
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 5, 2019 · Synced Oct 30, 2026, 8:40 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Genetic Causes of Growth Disorders

NCT02311322
View directory record Official record
Conditions
Short Stature, Growth Disorder, Syndromic Growth Disorder, Tall Stature
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Not listed
Enrollment
334 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 16, 2023 · Synced Oct 30, 2026, 8:40 PM EDT
Completed Phase 2 Interventional

Arsenic Trioxide in Treating Patients With Acute Myeloid Leukemia

NCT00005795
View directory record Official record
Conditions
Leukemia
Interventions
arsenic trioxide
Drug
Lead sponsor
Northwestern University
Other
Eligibility
16 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 11, 2012 · Synced Oct 30, 2026, 8:40 PM EDT
Terminated Phase 1 Interventional

rhPTH Therapy for Low Turnover Bone Fragility

NCT00145886
View directory record Official record
Conditions
Osteopetrosis
Interventions
rhPTH
Drug
Lead sponsor
University of Chicago
Other
Eligibility
20 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 12, 2016 · Synced Oct 30, 2026, 8:40 PM EDT
Recruiting Phase 1 Interventional

Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling

NCT05857969
View directory record Official record
Conditions
Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Large Cell Lymphoma, Refractory Childhood Acute Lymphoblastic Leukemia, Refractory Childhood Hodgkin Lymphoma, Refractory Childhood Malignant Germ Cell Neoplasm, Recurrent Childhood Brain Tumor, Recurrent Childhood Brainstem Glioma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Childhood Ependymoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Gliosarcoma, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Childhood Malignant Solid Neoplasm, Recurrent Childhood Malignant Solid Neoplasm, Recurrent Childhood Malignant Neoplasm, Refractory Childhood Malignant Neoplasm
Interventions
Functional Precision Medicine
Device
Lead sponsor
Florida International University
Other
Eligibility
1 Day to 21 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 30, 2026, 8:40 PM EDT
Active, not recruiting Phase 3 Interventional

Setrusumab vs Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta

NCT05768854
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
Bisphosphonate, Setrusumab
Drug · Biological
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
2 Years to 6 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
13
States / cities
Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 30, 2026, 8:40 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Losartan to Improve Hip Microfracture

NCT04212650
View directory record Official record
Conditions
Hip Osteoarthritis, Hip Impingement Syndrome, Cartilage Damage, Fibrosis
Interventions
Losartan, Placebo
Drug · Other
Lead sponsor
Steadman Philippon Research Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Vail, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Oct 30, 2026, 8:40 PM EDT